Overview

Study to Evaluate Safety of Vitamin D Receptor Activators in Patients Ages 0 to 16 With Chronic Kidney Disease Stage 5 Receiving Peritoneal Dialysis Within Current Clinical Practice

Status:
Terminated

Trial end date:
2012-05-01

Target enrollment:

Participant gender:

Summary

The objective of this study was to observe the safety of paricalcitol utilization in pediatric participants (ages 0 to 16 years old) being treated for secondary hyperparathyroidism (SHPT). Participants were to be followed for a minimum of 3 months and up to approximately 36 months to monitor the incidence of hypercalcemia (high calcium levels in blood).

Details

Lead Sponsor:

AbbVie (prior sponsor, Abbott)

Collaborator:

North America Pediatric Renal Trials and Collaborative Studies (NAPRTCS)

Treatments:

Calcitriol
Ergocalciferols